48
Markets2h 30m ago

Investment firms UBS and Franklin Templeton project healthcare stocks are set for a turnaround, citing factors like GLP-1 weight-loss drugs, AI in drug discovery, and an aging global population.

Archive Window: 7 Days Left

global

Who
UBS, Franklin Templeton
What
Investment firms UBS and Franklin Templeton project healthcare stocks are set for a turnaround, citing factors like GLP-1 weight-loss drugs, AI in drug discovery, and an aging global population.
When
Tue, 16 Jun 2026 09:40:02 GMT · 2h 30m ago
Where
global ·
Why
Despite underperforming the S&P 500 and Nasdaq 100 year-to-date, healthcare stocks are predicted to rise due to new growth drivers and current undervaluation.
The Frontline Impact

How this affects you

UBS global head of equities stated GLP-1 drugs could create a market exceeding $100 billion by 2030, suggesting significant growth for pharmaceutical stocks in the healthcare sector. This outlook indicates a potential shift in investment focus from technology to healthcare.

Story chain

3 events in this thread
  1. Markets2h 30m ago
    UBS and Franklin Templeton indicate that healthcare stocks are poised for a turnaround, citing reasons like GLP-1 weight-loss drugs, AI in drug discovery, and an aging global population.
    Open article
  2. Markets2h 30m ago
    UBS and Franklin Templeton stated this month that healthcare stocks are set to stage a turnaround and outperform the market.
    Open article
  3. Currently Reading2h 30m ago
    Investment firms UBS and Franklin Templeton project healthcare stocks are set for a turnaround, citing factors like GLP-1 weight-loss drugs, AI in drug discovery, and an aging global population.

Verified Sources & Citations